[{"id":"f5fa0587-a42c-4ae9-b704-89c0b50791d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02709993","created_at":"2021-01-18T13:14:51.985Z","updated_at":"2024-07-02T16:36:54.629Z","phase":"Phase 1/2","brief_title":"Consolidation Therapy in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02709993","lead_sponsor":"Kiromic, Inc.","biomarkers":" HLA-A • PTTG1","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • PTTG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BSK-01"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2017","start_date":" 07/28/2017","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 10/31/2020","study_completion_date":" 10/31/2020","last_update_posted":"2019-10-14"},{"id":"35ecd9e1-5591-4a15-9b32-e32d19fcfd20","acronym":"","url":"https://clinicaltrials.gov/study/NCT02705703","created_at":"2021-01-18T13:12:40.330Z","updated_at":"2024-07-02T16:37:07.408Z","phase":"Phase 1/2","brief_title":"Consolidation Therapy in Patients With Metastatic Solid Malignancies","source_id_and_acronym":"NCT02705703","lead_sponsor":"Kiromic, Inc.","biomarkers":" HER-2 • HLA-A • CTAG1B","pipe":" | ","alterations":" HER-2 expression • HLA-A*02 • HLA-A*24","tags":["HER-2 • HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BSK-01"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2017","start_date":" 07/28/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 01/31/2019","study_completion_date":" 01/31/2019","last_update_posted":"2018-08-28"},{"id":"df1c5be5-ccb4-434c-b932-cc2846caf32a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02223312","created_at":"2021-01-18T10:25:19.825Z","updated_at":"2024-07-02T16:37:07.453Z","phase":"Phase 1/2","brief_title":"Therapy for Progressive and/or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT02223312","lead_sponsor":"Kiromic, Inc.","biomarkers":" CSF2 • PTTG1","pipe":" | ","alterations":" HLA-A*24","tags":["CSF2 • PTTG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BSK-01"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2017","start_date":" 07/28/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 01/31/2019","study_completion_date":" 01/31/2019","last_update_posted":"2018-08-28"}]